680 related articles for article (PubMed ID: 34027753)
21. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
22. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis.
Silverberg JI; Gelfand JM; Margolis DJ; Fonacier L; Boguniewicz M; Schwartz LB; Simpson E; Grayson MH; Ong PY; Fuxench ZCC
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):464-468.e3. PubMed ID: 30003968
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.
Schmid-Grendelmeier P; Gooderham MJ; Hartmann K; Konstantinou GN; Fellmann M; Koulias C; Clibborn C; Biswas P; Brunner PM
Allergy; 2024 Jan; 79(1):174-183. PubMed ID: 37988255
[TBL] [Abstract][Full Text] [Related]
24. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
[TBL] [Abstract][Full Text] [Related]
25. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
[TBL] [Abstract][Full Text] [Related]
26. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
Heratizadeh A; Haufe E; Stölzl D; Abraham S; Heinrich L; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach-Renz P; Asmussen A; Schwarz B; Bell M; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Biedermann T; Weidinger S; Schmitt J; Werfel T;
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1263-1272. PubMed ID: 31721316
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal course and phenotypes of health-related quality of life in adults with atopic dermatitis.
Schwartzman G; Lei D; Ahmed A; Chavda R; Gabriel S; Silverberg JI
Clin Exp Dermatol; 2022 Feb; 47(2):359-372. PubMed ID: 34623642
[TBL] [Abstract][Full Text] [Related]
28. Associations Between Shower and Moisturizing Practices with Atopic Dermatitis Severity: A Prospective Longitudinal Cohort Study.
Rakita U; Kaundinya T; Silverberg JI
Dermatitis; 2023; 34(5):425-431. PubMed ID: 36917546
[No Abstract] [Full Text] [Related]
29. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults.
Barrett A; Hahn-Pedersen J; Kragh N; Evans E; Gnanasakthy A
Patient; 2019 Oct; 12(5):445-459. PubMed ID: 31270775
[TBL] [Abstract][Full Text] [Related]
30. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
[TBL] [Abstract][Full Text] [Related]
31. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].
Haufe E; Abraham S; Heratizadeh A; Harder I; Zink A; Weisshaar E; Kleinheinz A; von Kiedrowski R; Worm M; Bell M; Wollenberg A; Neubert K; Staubach-Renz P; Hilgers M; Bieber T; Fell I; Homey B; Effendy I; Mempel M; Schäkel K; Beissert S; Weidinger S; Werfel T; Schmitt J
Hautarzt; 2018 Oct; 69(10):815-824. PubMed ID: 30191254
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
[TBL] [Abstract][Full Text] [Related]
33. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074
[TBL] [Abstract][Full Text] [Related]
34. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
35. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
37. Severity strata for five patient-reported outcomes in adults with atopic dermatitis.
Vakharia PP; Chopra R; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Simpson EL; Silverberg JI
Br J Dermatol; 2018 Apr; 178(4):925-930. PubMed ID: 29048751
[TBL] [Abstract][Full Text] [Related]
38. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life.
Coutanceau C; Stalder JF
Dermatology; 2014; 229(3):248-55. PubMed ID: 25196258
[TBL] [Abstract][Full Text] [Related]
39. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
[TBL] [Abstract][Full Text] [Related]
40. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults.
Silverberg JI; Chiesa Fuxench ZC; Gelfand JM; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Simpson EL; Ong PY
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):729-734.e4. PubMed ID: 30092267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
